鲁碧楠
博士,副教授,硕士生导师
1984年生人,汉族,现为中央民族大学药学院教师。从事民族药学及药理毒理学研究,主要研究方向为糖尿病及其并发症发病机制与中药/民族药干预研究。主持国家自然科学基金青年基金项目1项,在Clin Transl Med、J Ethnopharmacol、Ecotoxicol Environ Saf、中草药(英文版)、中国新药杂志等国内外学术期刊上发表论文20余篇,出版专著1部;获授权发明专利1项。
个人教育经历:
起止年月 | 毕业院校 | 专业 | 学位 |
2003.09-2007.06 | 大连医科大学 | 药学 | 理学学士 |
2007.09-2010.06 | 大连医科大学 | 微生物与生化药学 | 医学硕士 |
2010.07-2013.06 | 中央民族大学 | 中国少数民族传统医学 | 法学博士 |
代表性论文:
[1] Zhang YJ, Zhang YS, Yao RF, He X, Zhao LY, Zuo XY, Lu BN * and Pang ZR*. Ferroptosis-related DEGs serve as new biomarkers in ischemic stroke and identification of therapeutic drugs. Frontiers in Nutrition 2022; 9:1010918. (A+,IF=6.576)
[2] Zhang Y#, Fan L#, Yao R, He X, Zhao L, Lu B* and Pang Z*. ACEs family genes: Important molecular links between lung cancer and COVID-19. Clin Transl Med. 2021; 11(12): e615. (A+,IF=11.492)
[3] Zhang YJ, Zhao LY, He X, Yao RF, Lu F, Lu BN* and Pang ZR*. CBXs-related prognostic gene signature correlates with immune microenvironment in gastric cancer. Aging (Albany NY). 2022; 14(15):6227-6254. (A,IF=5.682)
[4] Niu H#, Fan L#, Zhao L, Yao R, He X, Lu B* and Pang Z*. The therapeutic mechanism of PuRenDan for the treatment of diabetic nephropathy: Network pharmacology and experimental verification. J Ethnopharmacol. 2022; 293:115283. (A,IF=4.36)
[5] Fan L, Niu H, Zhao L, Yao R, He X, Lu B*and Pang Z*. Purendan alleviates non-alcoholic fatty liver disease in aged type 2 diabetic rats via regulating mTOR/S6K1/SREBP-1c signaling pathway. Biomed Pharmacother. 2022; 148:112697. (A,IF=6.53)
[6] Guo R, Lv J, Xu H, Bai Y, Lu B* and Han Y*. A systems toxicology approach to explore toxicological mechanisms of fluoroquinolones-induced testis injury. Ecotoxicol Environ Saf. 2021; 228:113002. (A,IF=6.291)
[7] Zhang Y, Wei H, Fan L, Fang M, He X, Lu B* and Pang Z*. CLEC4s as Potential Therapeutic Targets in Hepatocellular Carcinoma Microenvironment. Front Cell Dev Biol. 2021; 9: 681372. (A,IF=6.684)